Note - full abstracts will be released on Tuesday January 17th at 6 pm ET
The poster and presentation titles are now available, here are a few of interest:
Abstract #211 (Biosante Pharma) Friday 1/20
Not 100% positive but this should be a GVAX cancer vaccine trial at Johns Hopkins
Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer.
Dung T. Le, MD
Poster Board: #B19
Abstract #213 (Infinity Pharma) Friday 1/20 1145 am to 145 pm
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
Donald A. Richards, MD, PhD
Poster Board: #B21
Abstract #467 (Synta Pharma) Saturday 1/21
Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer.
Andrea Cercek, MD
Poster Board: #B38
The poster and presentation titles are now available, here are a few of interest:
Abstract #211 (Biosante Pharma) Friday 1/20
Not 100% positive but this should be a GVAX cancer vaccine trial at Johns Hopkins
Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer.
Dung T. Le, MD
Poster Board: #B19
Abstract #213 (Infinity Pharma) Friday 1/20 1145 am to 145 pm
A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.
Donald A. Richards, MD, PhD
Poster Board: #B21
Abstract #467 (Synta Pharma) Saturday 1/21
Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer.
Andrea Cercek, MD
Poster Board: #B38
RSS Feed
